Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients

Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, ... Read More